Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
RLAY - Relay Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$26.25
DETAILS
HIGH:
$31.00
LOW:
$18.00
MEDIAN:
$27.50
CONSENSUS:
$26.25
UPSIDE:
39.11%
Stock News
Allianz Asset Management GmbH Makes New $750,000 Investment in Relay Therapeutics, Inc. $RLAY
Allianz Asset Management GmbH acquired a new stake in Relay Therapeutics, Inc. (NASDAQ: RLAY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 40,100 shares of the company's stock, valued at approximately $750,000. Other large investors have also recently made changes
Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY
Frazier Life Sciences Management L.P. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,015,693 shares of the company's stock, valued at approximately $19,004,000. Frazier Life Sciences
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
Bank of America Corp DE raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 86.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,937,695 shares of the company's stock after purchasing an additional 896,746 shares during the
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m.
Is Relay Therapeutics a Buy After Promising Trial Results?
Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.
Why Relay Therapeutics Stock Popped on Wednesday
This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and maintained their buy ratings.
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and strong Phase 3 data support its differentiated tolerability and efficacy profile, targeting both oncology and vascular anomalies. RLAY's $642M cash position, recent ATM raise, and cost controls provide runway into 2029, enabling pivotal trials and pipeline expansion without near-term financing risk.
Price Targets
Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
$29.00
(was $20.74)
H.C. Wainwright
Relay Therapeutics price target raised to $30 from $27 at Barclays
$30.00
(was $19.75)
Etzer Darout
·
Barclays
Relay Therapeutics price target raised to $31 from $22 at Goldman Sachs
$31.00
(was $19.18)
Salveen Richter
·
Goldman Sachs
Relay Therapeutics initiated with a Buy at Canaccord
$29.00
(was $19.51)
John Newman
·
Canaccord Genuity
Relay Therapeutics (RLAY) PT Raised to $26 at Guggenheim
$26.00
(was $13.53)
Brad Canino
·
Guggenheim
Relay Therapeutics price target raised to $28 from $25 at H.C. Wainwright
$28.00
(was $13.53)
H.C. Wainwright
Relay Therapeutics price target raised to $27 from $21 at Barclays
$27.00
(was $12.07)
Barclays
Relay Therapeutics price target raised to $26 from $23 at Raymond James
$26.00
(was $12.88)
UBS
Relay Therapeutics price target raised to $25 from $19 at H.C. Wainwright
$25.00
(was $13.03)
H.C. Wainwright
Relay Therapeutics price target raised to $18 from $14 at Oppenheimer
$18.00
(was $14.95)
Oppenheimer
Relay Therapeutics price target raised to $21 from $17 at Wells Fargo
$21.00
(was $14.95)
Wells Fargo
Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
$22.00
(was $14.95)
Salveen Richter
·
Goldman Sachs
Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim
$22.00
(was $10.81)
Brad Canino
·
Guggenheim
Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer
$14.00
(was $7.43)
Oppenheimer
Relay Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
$13.00
(was $7.80)
Wells Fargo
Relay Therapeutics (RLAY) PT Raised to $19 at H.C. Wainwright
$19.00
(was $7.60)
Robert Burns
·
H.C. Wainwright
Relay Therapeutics upgraded to Buy from Hold at Jefferies
$16.00
(was $9.51)
Akash Tewari
·
Jefferies
Relay Therapeutics price target raised to $17 from $14 at Barclays
$17.00
(was $9.51)
Peter Lawson
·
Barclays
Relay Therapeutics (RLAY) PT Lowered to $20 at BofA Securities
$20.00
(was $6.41)
Jason Gerberry
·
Bank of America Securities
Barclays Upgrades Relay Therapeutics (RLAY) to Overweight
$15.00
(was $6.68)
Peter Lawson
·
Barclays